Nantkwest Inc (NASDAQ:NK) has received a consensus rating of “Hold” from the seven analysts that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $5.33.
Several analysts have recently weighed in on NK shares. Zacks Investment Research raised shares of Nantkwest from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a research note on Friday, January 12th. Raymond James Financial reissued a “hold” rating on shares of Nantkwest in a research note on Monday, December 11th. Finally, BidaskClub cut shares of Nantkwest from a “sell” rating to a “strong sell” rating in a research note on Friday, January 19th.
Shares of Nantkwest (NK) opened at $3.95 on Tuesday. Nantkwest has a one year low of $2.71 and a one year high of $8.45. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. The firm has a market cap of $313.85 and a P/E ratio of -3.35.
Nantkwest Company Profile
NantKwest, Inc is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.